Leucine-rich repeat kinase 2 (LRRK2) inhibitors

Patent Number: US-11958865-B1

Publication Year: 2024

Granted Year: 2024

Application Year: 2023

Priority Year: 2022

Jurisdictions: US

Status: Active

Inventors:

JENSEN THOMAS JENSEN THOMAS ANDERSEN THOMAS ANDERSEN THOMAS JESSING MIKKEL JESSING MIKKEL NIELSEN JACOB NIELSEN JACOB DAVER HENRIK DAVER HENRIK JONES CHRISTOPHER RICHARD JONES CHRISTOPHER RICHARD

Applicants:

  1. Lundbeck (Denmark)
    2. [NORA names: Lundbeck; Private Research; Denmark; Europe, EU; Nordic; OECD]

Abstract

The present invention is directed to compounds of formula IIa

embedded image

These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.

Patent Family Records (2)

MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS  

H LUNDBECK AS, Ligand Pharmaceuticals (United Kingdom), Lundbeck (Denmark), VERNALIS R&D LTD JENSEN THOMAS, ANDERSEN THOMAS, JESSING MIKKEL, (...more)

2024, WO-2024056775-A1

Leucine-rich repeat kinase 2 (LRRK2) inhibitors

H Lundbeck AS, Lundbeck (Denmark) JENSEN THOMAS, ANDERSEN THOMAS, JESSING MIKKEL, (...more)

2024, US-11958865-B1

Data Provider: Digital Science

LINKS
+

External Systems

SUBJECTS
+

PATENT CATEGORIES
+

METRICS
+

Citation Metrics

Times Cited in Patents: 0external link

References to Patents: 38external link

References to Publications: 8external link